3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Hepatocellular
16
Carcinoma, Non-Small-Cell Lung
8
Urinary Bladder Neoplasms
4
Liver Neoplasms
4
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Colorectal Neoplasms
2
Biliary Tract Neoplasms
2
Urothelial Cancer
1
Unresectable Hepatocellular Carcinoma
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Malignancies
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Hypertension, Portal
1
Hepato Cellular Carcinoma
1
Hematologic Neoplasms
1
Fibrosis
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Interventions
Magnetic Resonance Spectroscopy
47
enzalutamide
46
apalutamide
36
Specimen Handling
30
Androgen Antagonists
30
Abiraterone Acetate
29
Radiosurgery
26
Prednisone
25
darolutamide
24
Docetaxel
23
Pluvicto
21
abiraterone
19
Radiotherapy
19
Biopsy
17
Leuprolide
15
Surveys and Questionnaires
11
Radiation
11
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
11
relugolix
10
gallium 68 PSMA-11
10
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
10
Standard of Care
10
Nivolumab
10
cabazitaxel
9
Triptorelin Pamoate
9
bicalutamide
8
Carboplatin
8
pembrolizumab
7
olaparib
7
niraparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
tremelimumab
×
90 days
×
Clear all
No trials found.